• Neovascular (wet) age-related macular degeneration (AMD):
    • 2mg (0.05mL) intravitreally every 4 weeks for the first 3 injections then 2 mg every 8 weeks
    • May consider 12 weekly maintenance dosing after 1 year of treatment
  • Macular edema following retinal vein occlusion (RVO):
    • 2mg intravitreally every 4 weeks
  • Diabetic Macular Edema (DME):
    • 2mg (0.05mL) intravitreally every 4 weeks for the first 5 injections then 2mg every 8 weeks
    • Some pts may require every 4 weeks maintenance dosing

Injection: 40mg/mL

  • Should not be used with swelling inside the eyes or any type of infection in or around the eyes.

It binds and inhibits vascular endothelial growth factor A (VEGF-A) and placental growth factor (PIGF), decreasing neovascularization and vascular permeability.

  • Conjunctival hemorrhage
  • Ocular pain
  • Cataracts
  • Vitreous floaters
  • IOP increased
  • Vitreous detachment
  • Corneal erosion
  • Conjunctival hyperemia
  • Arterial thromboembolism
  • Retinal pigment epithelial detachment
  • Foreign body sensation
  • Increased lacrimation
  • Injection site pain
  • Retinal pigment epithelial tear
  • Blurred vision
  • Ocular inflammation
  • Hypersensitivity to components
  • Ocular or periocular infection
  • Active intraocular inflammation

None significant

                          Drug Status

Availability Prescription only
Pregnancy Category C
Breastfeeding Can be used
Schedule Not controlled
BRAND NAME STRENGTH FORMULATION PACK SIZE MANUFACTURER DISTRIBUTOR
Eylea 40mg/mL Injection 3mL Regeneron Pharma Bayer Schering